← All companies ← IMPPP Manual INFY → ← IMNM Pharmaceuticals INDV →
INCR, Intercure Ltd.
InterCure has 13 direct subsidiaries: Canndoc's operations are focused on the production, manufacturing, exporting and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use.
Cannolam's operations are focused on the establishing and operating of dedicated pharmacies for the distribution of pharmaceutical-grade cannabis under the brand name "Givol", including "Cookies"-branded location.
Leon Pharm's operations are focused on managing and operating a leading private pharmacy chain across major cities in Israel, specializing in dispensing medical cannabis products and personalized pharmaceutical services.
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
- What moves the needle
- Operating margin has reached 13% at its best but run negative through the cycle (median −28%) on a 30% gross margin — so the question is which reading is truer: whether the median was pulled below zero by one-off charges, by the cycle, or by spending it is still growing into, and whether it settles back at a profit. Inventory runs near 30% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median −4%, above 15% in 0 of 6 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
The record, 2019–2024
realized figures from each filing · older years to the left| 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | TTMTTMDec 2024 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| ₪9M | ₪65M | ₪220M | ₪389M | ₪356M | ₪239M | ₪239M | RevenueRevenue |
| 16% | 47% | 44% | 41% | 30% | 15% | 15% | Gross marginGross mgn |
| (₪3M) | (₪38M) | ₪28M | ₪51M | (₪42M) | (₪67M) | (₪67M) | Operating incomeOp. inc. |
| −38.3% | −59.0% | 12.8% | 13.0% | −11.7% | −28.1% | −28.1% | Operating marginOp. mgn |
| (₪6M) | (₪37M) | ₪5M | ₪45M | (₪62M) | (₪68M) | (₪68M) | Net incomeNet inc. |
| Cash flow & returns | |||||||
| (₪12M) | ₪8M | ₪30M | ₪51M | (₪54M) | (₪67M) | (₪67M) | Operating cash flowOp. cash |
| ₪828K | ₪3M | ₪7M | ₪12M | ₪13M | ₪15M | ₪15M | DepreciationDeprec. |
| (₪7M) | ₪42M | ₪18M | (₪5M) | (₪5M) | (₪15M) | (₪15M) | Working capital & otherWC & other |
| ₪28M | ₪21M | ₪14M | ₪20M | ₪3M | ₪4M | ₪4M | CapexCapex |
| 315.3% | 32.0% | 6.4% | 5.1% | 0.7% | 1.8% | 1.8% | Capex / revenueCapex/rev |
| (₪12M) | ₪5M | ₪23M | ₪40M | (₪56M) | (₪71M) | (₪71M) | Owner earningsOwner earn. |
| −138.9% | 7.1% | 10.4% | 10.2% | −15.8% | −29.9% | −29.9% | Owner earnings marginOE mgn |
| (₪40M) | (₪13M) | ₪16M | ₪32M | (₪56M) | (₪71M) | (₪71M) | Free cash flowFCF |
| −444.9% | −19.9% | 7.3% | 8.1% | −15.8% | −29.9% | −29.9% | Free cash flow marginFCF mgn |
| -1% | -13% | 4% | 10% | -6% | -11% | -11% | ROICROIC |
| -2% | -14% | 1% | 9% | -14% | -17% | -17% | Return on equityROE |
| −2% | −14% | 1% | 9% | −14% | −17% | −17% | Retained to equityRetained/eq |
| Balance sheet | |||||||
| ₪27M | ₪38M | ₪197M | ₪233M | ₪101M | ₪79M | ₪79M | Cash & investmentsCash+inv |
| — | ₪12M | ₪17M | ₪37M | ₪60M | ₪52M | ₪52M | ReceivablesReceiv. |
| — | ₪19M | ₪62M | ₪140M | ₪105M | ₪120M | ₪120M | InventoryInvent. |
| — | ₪32M | ₪80M | ₪177M | ₪166M | ₪172M | ₪172M | Operating working capitalOper. WC |
| — | ₪77M | ₪336M | ₪527M | ₪419M | ₪392M | ₪392M | Current assetsCur. assets |
| — | ₪30M | ₪194M | ₪313M | ₪226M | ₪227M | ₪227M | Current liabilitiesCur. liab. |
| — | 2.6× | 1.7× | 1.7× | 1.9× | 1.7× | 1.7× | Current ratioCurr. ratio |
| — | ₪190M | ₪268M | ₪284M | ₪221M | ₪225M | ₪225M | GoodwillGoodwill |
| ₪282M | ₪326M | ₪697M | ₪958M | ₪787M | ₪763M | ₪763M | Total assetsAssets |
| — | ₪745K | ₪82M | ₪227M | ₪170M | ₪183M | ₪183M | Total debtDebt |
| — | (₪37M) | (₪114M) | (₪6M) | ₪69M | ₪105M | ₪105M | Net debt / (cash)Net debt |
| ₪256M | ₪275M | ₪448M | ₪501M | ₪455M | ₪397M | ₪397M | Shareholders’ equityEquity |
| Per share | |||||||
| 23.3M | 25.4M | 38.5M | 45.4M | 45.6M | 45.9M | 45.9M | Shares out (diluted)Shares |
| ₪0.38 | ₪2.56 | ₪5.71 | ₪8.57 | ₪7.80 | ₪5.21 | ₪5.21 | Revenue / shareRev/sh |
| ₪-0.25 | ₪-1.47 | ₪0.12 | ₪0.99 | ₪-1.36 | ₪-1.48 | ₪-1.48 | EPS (diluted)EPS |
| ₪-0.53 | ₪0.18 | ₪0.59 | ₪0.87 | ₪-1.23 | ₪-1.55 | ₪-1.55 | Owner earnings / shareOE/sh |
| ₪-1.70 | ₪-0.51 | ₪0.42 | ₪0.70 | ₪-1.23 | ₪-1.55 | ₪-1.55 | Free cash flow / shareFCF/sh |
| ₪1.21 | ₪0.82 | ₪0.36 | ₪0.44 | ₪0.06 | ₪0.10 | ₪0.10 | Cap. spending / shareCapex/sh |
| ₪11.00 | ₪10.81 | ₪11.64 | ₪11.05 | ₪9.99 | ₪8.65 | ₪8.65 | Book value / shareBVPS |
The diluted share count moved ×1.52 into 2021 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
| 5-yr | 5-yr | |
|---|---|---|
| Revenue / share | +68.5%/yr | +68.5%/yr |
| Capital spending / share | −39.8%/yr | −39.8%/yr |
| Book value / share | −4.7%/yr | −4.7%/yr |
The record, charted
FY2019–2024Each measure over its full record; the current point and the worst year marked.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedEach year's operating cash, by what management did with it: the mix, and how it drifts.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2024 the business reported a ₪68M loss but (₪71M) of owner earnings: ₪4M less than the profit line, taken out by capital spending and the timing of cash.
| FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|
| Reported net income | (₪68M) | (₪62M) | ₪45M | ₪5M | (₪37M) |
| Depreciation & amortizationnon-cash charge added back | +₪15M | +₪13M | +₪12M | +₪7M | +₪3M |
| Working capital & othertiming of cash in and out, other non-cash items | −₪15M | −₪5M | −₪5M | +₪18M | +₪42M |
| Cash from operations | (₪67M) | (₪54M) | ₪51M | ₪30M | ₪8M |
| Maintenance capital expenditurethe spending needed just to hold position and volume | −₪4M | −₪3M | −₪12M | −₪7M | −₪3M |
| Owner earnings | (₪71M) | (₪56M) | ₪40M | ₪23M | ₪5M |
| Growth capital expenditurediscretionary; spent to get bigger, not to stand still | — | — | −₪8M | −₪7M | −₪18M |
| Free cash flow | (₪71M) | (₪56M) | ₪32M | ₪16M | (₪13M) |
| Owner-earnings marginowner earnings ÷ revenue | -30% | -16% | 10% | 10% | 7% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- Interest expense not tagged in the data
What this means
No usable interest-expense line was tagged in the filing data, but the balance sheet carries real net debt — so the interest burden here is unknown, not absent. Read the debt on the net-debt check below.
- Net debt against an operating lossCash ₪78M + ST investments ₪333K − debt ₪183M
What this means
Netting ₪79M of cash and short-term investments against ₪183M of debt leaves ₪105M owed, with no operating profit this year to measure it against — understand that combination before anything else about the company. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Not enough data
What this means
The filing data didn't include the inputs for this check.
Is it a good business?
- Below average through the cycle6-yr median, range -13%–10%; -11% latest = NOPAT (₪53M) ÷ invested capital ₪502MIndustry peers: median -37%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 6 years (it ran -11% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- Consumes cash through the cycle6-yr median margin, range -139%–10%; latest (₪71M) = operating cash (₪67M) − maintenance capex ₪4MIndustry peers: median -53%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -30% of revenue this year, a -16% median across 6 years.
- Are earnings backed by cash? (₪67M)Loss, and burning cashNet income (₪68M) · cash from operations (₪67M)
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? 0.28×HarvestingCapex ₪4M ÷ depreciation ₪15M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 0 of 4 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size —Revenue ≥ $2B (a dollar floor) · ₪239M
What this means
Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.
- Strong liquidity NearCurrent ratio ≥ 2× · 1.73×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt NearDebt ≤ working capital · ₪183M vs ₪165M WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability MissA profit every year (6-yr record) · 4 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record MissUninterrupted dividends · none paid
What this means
An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.
- Earnings growth —Earnings +33% over the record · —
What this means
Earnings were negative early in the record, a growth rate isn't meaningful.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are ₪-0.52/share (latest year ₪-1.24), the averaged base the calculator's gate runs on, and book value is ₪7.26/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2019–2024
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 2 of 6
What this means
Lost money in 4 year(s), look at what happened there before trusting the average.
- Return on capital ≥ 15% 0 of 5 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin −28% → −9% (3-yr avg ends)
What this means
Through the cycle the operating margin widened — about −28% early to −9% lately, median −28% — pricing power intact or improving.
- Reinvestment, incremental ROIC −4%
What this means
Reinvested capital came back at a negative incremental return over this window — the invested base grew while operating profit did not. The filings show where it went.
- Worst year 2020 · −59.0% op. margin
What this means
Operations went underwater in 2020, understand why before trusting the good years.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of fiscal year-end, Dec 31, 2024Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments₪79M
- Receivables₪52M
- Inventory₪120M
- Other current assets₪141M
- Debt due within a year₪69M
- Other current liabilities₪157M
From the company's latest filing.
Acquisitions & goodwill
from the balance sheet & the 6-year cash-flow recordGoodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.
None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.
Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and write-downs summed across the 6-year record, from the company's own filings.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| ARVNArvinas Inc. | $263M | — | -306.3% | -37% | -118% |
| SDGRSchrodinger Inc. | $256M | 57% | -80.8% | -38% | -53% |
| INCRIntercure Ltd. | ₪239M | 36% | -19.9% | -4% | -4% |
| AKBAAkebia Therapeutics Inc. | $236M | 62% | -63.9% | -116% | -28% |
| ANABAnaptysBio Inc. | $235M | — | -206.9% | -25% | -172% |
| PBYIPuma Biotechnology Inc | $228M | 76% | 0.5% | -59% | 8% |
| IDYAIDEAYA Biosciences Inc. | $219M | — | -180.4% | -22% | -191% |
| VNDAVanda Pharmaceuticals Inc. | $216M | 89% | -2.4% | -0% | 9% |
| Group median | — | 62% | -72.3% | -31% | -41% |
The price
What a price has to assume.
What the price implies
reverse-DCFEnter the home-market price, not the US ADR quote. Intercure Ltd. reports in ILS, and every figure here (owner earnings, book value, the share count) is on that ILS, ordinary-share basis. Enter the price on the same basis: the local-exchange quote per ordinary share in ILS. A US ADR price in dollars bundles the ADR-to-ordinary ratio and the exchange rate, so it will not reconcile with these figures and would throw the multiple off.
Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Intercure Ltd. has delivered.
Intercure Ltd.’s latest year shows negative owner earnings, below the record’s own through-cycle owner earnings. So the tool opens on the through-cycle base, the cash it would earn at rest; clear the toggle below to read the latest year exactly as reported.
Through the cycle, Intercure Ltd. earns about ₪17M on its 7.1% median owner-earnings margin. This year’s −29.9% margin runs below that; the reported figure may understate a lean year. Normalize, below, values the price on that through-cycle figure rather than the latest year.
—
9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner earnings (₪71M) on 55M shares outstanding, per the 20-F cover, as of 2025-12-31; net debt ₪105M. The base opens on the through-cycle figure (the latest year sits off the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← IMPPP its page in the Manual INFY →
Industry order: ← IMNM the Pharmaceuticals chapter INDV →